William Blair Forecasts DENTSPLY SIRONA FY2024 Earnings

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) – Equities researchers at William Blair decreased their FY2024 EPS estimates for DENTSPLY SIRONA in a research report issued to clients and investors on Thursday, November 7th. William Blair analyst B. Vazquez now expects that the medical instruments supplier will earn $1.84 per share for the year, down from their previous estimate of $1.98. The consensus estimate for DENTSPLY SIRONA’s current full-year earnings is $1.84 per share. William Blair also issued estimates for DENTSPLY SIRONA’s Q1 2025 earnings at $0.41 EPS, Q2 2025 earnings at $0.52 EPS, Q3 2025 earnings at $0.53 EPS, Q4 2025 earnings at $0.50 EPS, Q2 2026 earnings at $0.58 EPS and Q3 2026 earnings at $0.58 EPS.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.02. The firm had revenue of $951.00 million during the quarter, compared to analysts’ expectations of $939.10 million. DENTSPLY SIRONA had a negative net margin of 10.59% and a positive return on equity of 12.62%. The company’s revenue for the quarter was up .4% compared to the same quarter last year. During the same quarter last year, the company posted $0.49 earnings per share.

A number of other analysts have also recently issued reports on the stock. Stifel Nicolaus cut their target price on shares of DENTSPLY SIRONA from $30.00 to $28.00 and set a “hold” rating for the company in a research note on Thursday, July 18th. Needham & Company LLC cut their target price on shares of DENTSPLY SIRONA from $34.00 to $29.00 and set a “buy” rating for the company in a research note on Friday, October 25th. Evercore ISI cut their target price on shares of DENTSPLY SIRONA from $29.00 to $27.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. StockNews.com upgraded shares of DENTSPLY SIRONA from a “hold” rating to a “buy” rating in a research note on Wednesday, November 6th. Finally, Leerink Partners cut shares of DENTSPLY SIRONA from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 7th. Six analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $29.50.

DENTSPLY SIRONA Stock Performance

Shares of XRAY stock opened at $17.65 on Monday. The stock has a market cap of $3.58 billion, a P/E ratio of -8.53, a P/E/G ratio of 0.97 and a beta of 1.02. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.25 and a quick ratio of 0.87. The company has a fifty day moving average price of $24.52 and a two-hundred day moving average price of $25.74. DENTSPLY SIRONA has a one year low of $17.21 and a one year high of $37.60.

Institutional Investors Weigh In On DENTSPLY SIRONA

A number of hedge funds have recently made changes to their positions in the stock. John G Ullman & Associates Inc. boosted its stake in shares of DENTSPLY SIRONA by 130.0% in the 3rd quarter. John G Ullman & Associates Inc. now owns 193,006 shares of the medical instruments supplier’s stock valued at $5,223,000 after purchasing an additional 109,083 shares in the last quarter. LMR Partners LLP acquired a new stake in shares of DENTSPLY SIRONA in the 3rd quarter valued at approximately $3,066,000. Quest Partners LLC boosted its stake in shares of DENTSPLY SIRONA by 379.8% in the 3rd quarter. Quest Partners LLC now owns 109,832 shares of the medical instruments supplier’s stock valued at $2,972,000 after purchasing an additional 86,939 shares in the last quarter. AM Squared Ltd boosted its stake in shares of DENTSPLY SIRONA by 69.4% in the 3rd quarter. AM Squared Ltd now owns 6,100 shares of the medical instruments supplier’s stock valued at $165,000 after purchasing an additional 2,500 shares in the last quarter. Finally, Natixis Advisors LLC boosted its stake in shares of DENTSPLY SIRONA by 21.1% in the 3rd quarter. Natixis Advisors LLC now owns 21,733 shares of the medical instruments supplier’s stock valued at $588,000 after purchasing an additional 3,787 shares in the last quarter. 95.70% of the stock is currently owned by institutional investors and hedge funds.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.